Clinical Trials for Adults | Functional and Neurocognitive Outcomes in Newly Diagnosed Glioblastoma Multiforme Patients Receiving a Bevacizumab-Containing Adjuvant Chemotherapy: A Prospective Cohort Study
All patients wtih high-grade gliomas undergo surgery, radiation, and chemotherapy. One addition to treatment has been the use of vascular endothelial growth factor inhibitors such as bevacizumab. In this study, we are seaking to examine prospectively the change in functional and neurocognitive outcomes in patients with newly diagnosed glioblastoma multiforme (GBM) who are receiving a bevacizumab-containing adjuvant chemotherapy.
- to examine prospectively the change in cardiaovascular and cerebrovascular function
- to examine prospectively the change in patient-report outcomes
- to examine the association between changes in primary and secondary outcomes.
- written informed consent prior to beginning specific protocol procedures
- histologically proven glioblastoma
- planned treatment with standard of care chemoradiation with radiotherapy and temozolomide
- planned treatment with adjuvant bevacizumab during chemoradiation
- >18 years and <70 years of age
- Karnofsky performance index >70%
- no documented cardiac or pulmonary disease
- no contraindications to exercise testing
- primary treating physician approval.